Literature DB >> 1639341

Postinfantile giant-cell transformation in hepatitis.

K Devaney1, Z D Goodman, K G Ishak.   

Abstract

Giant-cell hepatitis is a frequent pattern of liver injury in the neonate, but it is rare after infancy. Such cases have been attributed to autoimmune disease, to non-A, non-B hepatitis and, most recently, to paramyxovirus infection. To better define the entity of postinfantile (syncytial) giant-cell hepatitis, we reviewed 24 biopsy specimens from 20 patients with this finding, either alone or in combination with other diagnoses. The number of multinucleated giant cells varied greatly from one specimen to another. Varying degrees of portal inflammation appeared in all but one of the patients, and all had hepatitislike acinar inflammation associated with hepatocellular injury. Fibrosis was a common finding, varying from mild periportal fibrosis to established cirrhosis (33%). The changes were interpreted as acute giant-cell hepatitis in 25%, as CAH in 42% and as active cirrhosis in the remainder. The patients ranged in age from 2 to 80 yr, with a mean of 35 yr and a male/female ratio of approximately 1:1. The signs and symptoms of liver disease were present for more than 1 mo in most patients. A positive antinuclear antibody titer was found in seven of the patients. Three patients had a direct Coombs reaction and anemia. Overall, evidence of autoimmune disease was found in 40% of the patients. One patient had non-Hodgkin's lymphoma involving the liver. Only one patient had a history of blood transfusion or risk factors for hepatitis C. No patient underwent serological study for paramyxovirus antibodies. Liver tissue from one patient was examined ultrastructurally, but no viral particles could be identified.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1992        PMID: 1639341     DOI: 10.1002/hep.1840160208

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  13 in total

1.  Sinus histiocytosis with massive lymphadenopathy and giant cell hepatitis. An unreported association.

Authors:  Dimas Suarez-Vilela; Francisco Miguel Izquierdo-Garcia; José Luis Olcoz-Goñi
Journal:  Virchows Arch       Date:  2003-11-18       Impact factor: 4.064

2.  Giant cell hepatitis associated with systemic lupus erythematosus.

Authors:  A Cairns; R F McMahon
Journal:  J Clin Pathol       Date:  1996-02       Impact factor: 3.411

3.  Postinfantile giant cell hepatitis due to hepatitis E virus along with the presence of autoantibodies.

Authors:  Ozgür Harmanci; Ibrahim Koral Onal; Osman Ersoy; Bora Gürel; Cenk Sökmensüer; Yusuf Bayraktar
Journal:  Dig Dis Sci       Date:  2007-04-05       Impact factor: 3.199

Review 4.  Juvenile autoimmune hepatitis: Spectrum of the disease.

Authors:  Giuseppe Maggiore; Silvia Nastasio; Marco Sciveres
Journal:  World J Hepatol       Date:  2014-07-27

5.  Hepatitis - A induced Non Infantile Giant Cell Hepatitis.

Authors:  P Kinra; B M John
Journal:  Med J Armed Forces India       Date:  2011-07-21

6.  Syncytial giant cell hepatitis in a patient with chronic lymphocytic leukemia.

Authors:  Neil Gupta; Basile Njei
Journal:  J Dig Dis       Date:  2015-11       Impact factor: 2.325

7.  Post-infantile giant cell hepatitis in an elderly female patient with systemic lupus erythematosus.

Authors:  K Dohmen; S Ohtsuka; H Nakamura; K Arase; Y Yokogawa; R Asayama; S Kuroiwa; H Ishibashi
Journal:  J Gastroenterol       Date:  1994-06       Impact factor: 7.527

8.  Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management.

Authors:  Ye H Oo; Stefan G Hubscher; David H Adams
Journal:  Hepatol Int       Date:  2010-05-19       Impact factor: 6.047

9.  Giant cell hepatitis in adults.

Authors:  L Gábor; K Pál; S Zsuzsa
Journal:  Pathol Oncol Res       Date:  1997-09       Impact factor: 3.201

10.  Post-infantile giant cell hepatitis: histological and immunohistochemical study.

Authors:  S J Johnson; J Mathew; R N MacSween; M K Bennett; A D Burt
Journal:  J Clin Pathol       Date:  1994-11       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.